CARTESIAN THERAPEUTICS INC (RNAC)
US8162123025 - Common Stock
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit
Company to host conference call and webcast with key opinion leader on December 3, 2024, at 7:30 a.m. ET...
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company...
Cartesian Therapeutics (RNAC) Shares Cross Below 200 DMA
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting
Company continues to expect to hold an End-of-Phase 2 meeting with the FDA by year-end...
Cartesian Therapeutics Announces New Employment Inducement Grants
GAITHERSBURG, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company...
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.
Cartesian Therapeutics Announces New Employment Inducement Grant
GAITHERSBURG, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company...
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15
Descartes-15 observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing in...
RNAC Stock Earnings: Cartesian Therapeutics Beats EPS, Beats Revenue for Q2 2024
RNAC stock results show that Cartesian Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
RNAC Stock Earnings: Cartesian Therapeutics Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cartesian Therapeutics (NASDAQ:RNAC) just reported results for the second quart...
Cartesian Therapeutics Announces New Employment Inducement Grants
GAITHERSBURG, Md., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company...
Cartesian Therapeutics Announces New Employment Inducement Grants
GAITHERSBURG, Md., July 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company...
Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik
Dr. Malik to deepen strategic leadership and provide regulatory and clinical development innovation expertise...
Cartesian Therapeutics Plummets On 'Watershed Moment' For CAR-T Drugs
The company is the first to test a CAR-T drug against a placebo in patients with an autoimmune disease.
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company...
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
Trial to assess outpatient administration without lymphodepleting chemotherapy in patients with SLE...
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis
Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 observed to have a clinically...
Cartesian Therapeutics Announces New Employment Inducement Grant
GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company...
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
Topline data from Phase 2b trial of Descartes-08 in myasthenia gravis remains on track for mid-2024...
Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
GAITHERSBURG, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company), a clinical-stage biotechnology company...
RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q1 2024
RNAC stock results show that Cartesian Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cartesian Therapeutics (NASDAQ:RNAC) just reported results for the first quarte...
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Topline data from Phase 2b trial of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis on track for...
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
Proposals approved at Company’s special meeting of stockholders held March 27, 2024...
RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q4 2023
RNAC stock results show that Cartesian Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cartesian Therapeutics (NASDAQ:RNAC) just reported results for the fourth quart...
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis (MG) remains on...